Cosentyx

Cosentyx is a biologic that was approved for the treatment of psoriasis in 2015 and for the treatment of psoriatic arthritis in 2016.

What is Cosentyx?

Cosentyx (also known by its generic name secukinumab) was approved by the FDA in January 2015 for the treatment of moderate-to-severe plaque psoriasis in adults. In January 2016, the FDA also approved Cosentyx to treat adults with active psoriatic arthritis.

For patients with plaque psoriasis, Cosentyx is administered by injection under the skin at weeks 0, 1, 2, 3, and 4 and then every 4 weeks. Health care providers may recommend a different dosing schedule for patients with psoriatic arthritis.

To learn more, please visit the Cosentyx website.

Loudspeaker animated image

Cosentyx Receives FDA Approval for Psoriatic Arthritis

Hard-to-treat psoriasis and psoriatic arthritis improves significantly on the biologic drug.

Discover more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Keep up to date with the psoriatic disease field.

Start reading

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.